{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T01:32:36Z","timestamp":1780795956585,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22H04313"],"award-info":[{"award-number":["JP22H04313"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clinbiochem.2025.110949","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:55:18Z","timestamp":1747162518000},"page":"110949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Wide-range and high-throughput quantification of anamorelin in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry"],"prefix":"10.1016","volume":"138","author":[{"given":"Takahiro","family":"Sumimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2025.110949_b0005","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jcsm.13216","article-title":"Epidemiology, risk factors and impact of cachexia on patient outcome: results from the Japanese Lung Cancer Registry Study","volume":"14","author":"Shukuya","year":"2023","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.21873\/anticanres.16188","article-title":"The latest treatments for cancer cachexia: an overview","volume":"43","author":"Watanabe","year":"2023","journal-title":"Anticancer Res."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argil\u00e9s","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0020","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0025","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdu085","article-title":"Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0030","doi-asserted-by":"crossref","unstructured":"S. Blauwhoff-Buskermolen, M.A. de van der Schueren, H.M. Verheul, J.A. Langius, 'Pre-cachexia': a non-existing phenomenon in cancer?, Ann Oncol 25 (2014) 1668\u20131669. doi: 10.1093\/annonc\/mdu178.","DOI":"10.1093\/annonc\/mdu178"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0035","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/j.jpainsymman.2021.02.034","article-title":"Quality of Life and symptom burden improve in patients attending a multidisciplinary clinical service for cancer cachexia: a retrospective observational review","volume":"62","author":"Bland","year":"2021","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/SPC.0000000000000176","article-title":"Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective","volume":"9","author":"Borg","year":"2015","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/eje.0.1500447","article-title":"Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects","volume":"150","author":"Akamizu","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0055","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","article-title":"Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial","volume":"89","author":"Neary","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0060","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1210\/jcem.86.12.8111","article-title":"Ghrelin enhances appetite and increases food intake in humans","volume":"86","author":"Wren","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0065","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0070","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.8503009","article-title":"A nonpeptidyl growth hormone secretagogue","volume":"260","author":"Smith","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0075","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.14.14","article-title":"Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome","volume":"10","author":"Currow","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0080","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/14656566.2015.1041500","article-title":"Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC","volume":"16","author":"Zhang","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study","volume":"21","author":"Garcia","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0090","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.12-5-594","article-title":"Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers","volume":"12","author":"Garcia","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ghir.2008.12.003","article-title":"Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers","volume":"19","author":"Garcia","year":"2009","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0100","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0105","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","article-title":"Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial","volume":"24","author":"Takayama","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0110","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0115","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1002\/cncr.32406","article-title":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia","volume":"125","author":"Hamauchi","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0120","unstructured":"R. Blum, W. Polvino, Pharmacokinetic (PK) profile of RC-1291, a novel oral ghrelin mimetic for the treatment of cancer anorexia\/cachexia., Support Care Cancer 14:593 (2006) Abstract 03\u2013010."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0125","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1634\/theoncologist.11-7-732","article-title":"Complementary and alternative medicine during cancer treatment: beyond innocence","volume":"11","author":"Tascilar","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0130","unstructured":"Ono Pharmaceutical Co. Ltd, The drug interview form of Anamorelin Hydrochloride (ADLUMIZ\u00ae), 2023 (in Japanese). https:\/\/www.ono-oncology.jp\/system\/files\/2024-11\/ADM_IF_1.pdf. (Accessed 13 December 2024)."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5582\/ddt.2024.01049","article-title":"Determination of anamorelin concentration in human plasma using a simple high-performance liquid chromatography-ultraviolet detection method","volume":"18","author":"Yasu","year":"2024","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0140","unstructured":"Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. (Accessed December 6 2024)."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13080949","article-title":"Metabolism Study of Anamorelin, a GHSR1a receptor agonist potentially misused in sport, with human hepatocytes and LC-HRMS\/MS","volume":"13","author":"Gameli","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0150","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpdd.175","article-title":"An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin","volume":"4","author":"Leese","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5478\/MSL.2016.7.3.55","article-title":"LC-MS\/MS method for simultaneous analysis of growth hormone-releasing peptides and secretagogues in human urine","volume":"7","author":"Min","year":"2016","journal-title":"Mass Spectrometry Lett."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jssc.201501060","article-title":"Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry","volume":"39","author":"Thomas","year":"2016","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0170","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1210\/en.2006-0518","article-title":"The novel roles of liver for compensation of insulin resistance in human growth hormone transgenic rats","volume":"147","author":"Cho","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinbiochem.2025.110949_b0175","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2265.2002.01601.x","article-title":"The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults","volume":"57","author":"Yuen","year":"2002","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0180","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1254\/fpj.21046","article-title":"Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ\u00aeTablets), the first orally available drug for cancer cachexia with ghrelin-like action in Japan (in Japanese)","volume":"156","author":"Yasutomo","year":"2021","journal-title":"Folia Pharmacol. Jpn."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0185","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00228-016-2116-z","article-title":"Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients","volume":"72","author":"Sato","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2025.110949_b0190","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/dmd.122.001131","article-title":"Activation\/inactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy","volume":"51","author":"Wang","year":"2023","journal-title":"Drug Metab. Dispos."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025000785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025000785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:15:16Z","timestamp":1752567316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912025000785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":38,"alternative-id":["S0009912025000785"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110949","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wide-range and high-throughput quantification of anamorelin in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.110949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110949"}}